Mansouri, E., Assarehzadegan, M., Nejad-Dehbashi, F., Kooti, W. (2018). Effects of Pravastatin in Adriamycin-Induced Nephropathy in Rats. Iranian Journal of Pharmaceutical Research, 17(4), 1413-1419. doi: 10.22037/ijpr.2018.2290
Esrafil Mansouri; Mohammad-Ali Assarehzadegan; Fereshteh Nejad-Dehbashi; Wesam Kooti. "Effects of Pravastatin in Adriamycin-Induced Nephropathy in Rats". Iranian Journal of Pharmaceutical Research, 17, 4, 2018, 1413-1419. doi: 10.22037/ijpr.2018.2290
Mansouri, E., Assarehzadegan, M., Nejad-Dehbashi, F., Kooti, W. (2018). 'Effects of Pravastatin in Adriamycin-Induced Nephropathy in Rats', Iranian Journal of Pharmaceutical Research, 17(4), pp. 1413-1419. doi: 10.22037/ijpr.2018.2290
Mansouri, E., Assarehzadegan, M., Nejad-Dehbashi, F., Kooti, W. Effects of Pravastatin in Adriamycin-Induced Nephropathy in Rats. Iranian Journal of Pharmaceutical Research, 2018; 17(4): 1413-1419. doi: 10.22037/ijpr.2018.2290
Effects of Pravastatin in Adriamycin-Induced Nephropathy in Rats
1Cellular and Molecular Research Center, Department of Anatomical Sciences, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
2Department of Immunology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
3Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran.
Abstract
The aim of this study is to evaluate the effects of pravastatin on Adriamycin (ADR)-induced nephropathy and the mechanisms involved. Forty rats were divided into the following 4 groups: control, ADR (15 mg.kg-1, IP), ADR plus pravastatin (20 mg.kg-1 which was started 5 days prior to ADR injection), and ADR plus pravastatin (20 mg.kg-1 which was started 5 days after ADR injection). On day 20 after ADR injection, the animals were sacrificed. The results showed that administration of pravastatin decreased the levels of 24-h urinary protein (24-h UP), blood urea nitrogen (BUN), and creatinine (p < 0.05) which had increased after the injection of ADR; in addition, pravastatin reversed structural changes seen in ADR group. Furthermore, pravastatin elevated mRNA and protein expression of nephrin (p < 0.05) which had been reduced in ADR group. We conclude that pravastatin protects and treats renal injury induced by ADR.
Top